[1]杜 怿,李 灿,方 刚,等.医保药物经济性评价质量评估量表研究及启示[J].卫生经济研究,2020,(06):28-32.
　DU Yi,LI Can,FANG Gang,et al.Research and Enlightenment of Quality Assessment Scale for Medical Insurance Drugs' Economic Evaluation[J].Journal Press of Health Economics Research,2020,(06):28-32.
点击复制

医保药物经济性评价质量评估量表研究及启示
分享到：

卫生经济研究[ISSN:1004-7778/CN:33-1056/F]

卷:
期数:
2020年06期
页码:
28-32
栏目:
方法学应用
出版日期:
2020-06-04

文章信息/Info

Title:
Research and Enlightenment of Quality Assessment Scale for Medical Insurance Drugs' Economic Evaluation
作者:
杜 怿1; 李 灿1; 方 刚1; 王敏娇1; 江欣悦1; 柳鹏程1
1.中国药科大学国际医药商学院，江苏 南京 211198
Author(s):
DU Yi;  LI Can;  FANG Gang;  WANG Min-jiao;  JIANG Xin-yue;  LIU Peng-cheng
College of International Pharmaceutical Business，China Pharmaceutical University, Nanjing Jiangsu 211198,China
关键词:
药物经济学; 预算影响分析; 医疗保险; 量表; 质量评估
Keywords:
drugs' economic;  budget impact analysis;  medical insurance;  scale;  quality assessment
分类号:
R19
文献标志码:
A
摘要:
目的：研究医保谈判准入中药物经济性评价质量评估量表，为我国开展医保药物经济性评价质量评估提供参考。方法：通过文献研究法，对比分析目前药物经济性评价质量评估量表的研究方法及特征。结果：目前药物经济性评价质量评估量表大多使用文献研究和专家调查等方法研制，其中药物经济学评价质量评估量表的数量和质量明显高于预算影响分析质量评估量表，我国尚未开展预算影响分析质量评估量表研究。结论：建议随着方法学的不断发展，逐步改进并完善药物经济学评价质量评估量表，特别注意量表研制的特异性和全面性。
Abstract:
Objective To study the quality assessment scale for medical insurance drugs' economic evaluation, and provide references for the quality assessment of medical insurance drugs' economic evaluation in China. Methods The literature review method was used to compare and analyze the research methods and characteristics of the currently quality assessment scale for drug economic evaluation. Results At present, most of the quality assessment scales for drug economic evaluation are developed using literature research and expert surveys. The number and quality of quality assessment scales for drug economic evaluation are significantly higher than the budget impact analysis of quality assessment scales. China has not yet launched studies on the budget impact analysis of quality assessment scales. Conclusion It is suggested that gradually improve and improve the quality assessment scale for drug economic evaluation with the development of methodology, and pay more attentions on the specificity and comprehensiveness of the scale development.

参考文献/References:

[1] 柳鹏程，顾佳慧，白铭钰，等.中美两国医保预算影响分析研究文献的质量评估[J].中国药房，2019，30（12）：1684-1691.
[2] 徐端正.药物经济学及其分析[J].中国新药与临床杂志，2000（2）：139-142.
[3] 孔彩，付希婧，孙茂，等.国外药物经济学研究质量评估的经验及对我国的启示[J].中国卫生经济，2014，33（9）：62-65.
[4] 董雅琦，顾佳慧，柳鹏程.医保预算影响分析国际经验研究及对我国的启示[J].中国药房，2018，29（12）：1652-1657.
[5] Orlewska E，Mierzejewski P.Proposal of polish guidelines for conducting financial analysis and their comparison to existing guidance on budget impact in other countries[J].VALUE IN HEALTH，2004，7（1）：1-10.
[6] 胡善联.预算影响分析与药物经济学分析[J].中国药房，2004（3）：30-33.
[7] 顾佳慧，柳鹏程.浅析药物经济学评价与医疗保险预算影响分析的差异[J].中国药物经济学，2018，13（3）：40-44.
[8] Drummond M F，Jefferson T O.Guidelines for authors and peer reviewers of economic submissions to the BMJ[J].BRITISH MEDICAL JOURNAL，1996，313（7052）：275-283.
[9] Chiou C，Hay J W，Wallace J F，et al.Development and Validation of a Grading System for the Quality of Cost-Effectiveness Studies[J].Medical Care，2003，41（1）：32-44.
[10] Evers S，Goossens M，Vet H D，et al.Criteria List For Assessment Of Methodological Quality Of Economic Evaluations: Consensus on Health Economic Criteria[J].Int J Technol Assess Health Care，2005，21（2）：240-245.
[11] Philips Z，Bojke L，Sculpher M，et al.Good Practice Guidelines for Decision-Analytic Modelling in Health Technology Assessment[J].Pharmacoeconomics，2006，24（4）：355-371.
[12] Husereau D，Drummond M，Petrou S, et al.CONSOLIDATED HEALTH ECONOMIC EVALUATION REPORTING STANDARDS (CHEERS) STATEMENT[J].International Journal of Technology Assessment in Health Care，2013，29（2）：6.
[13] 高海亮，卢颖，姜婷婷，等.药物经济学评价报告质量评估指南[J].中国药物经济学，2019，14（2）：18-28.
[14] Van de Vooren K, Duranti S,Curto A，et al.A critical systematic review of budget impact analyses on drugs in the EU countries[J].Appl Health Econ Health Policy，2014，12（1）：33-40.
[15] 马爱霞，钱焊森，张籍元，等.中国与加拿大预算影响分析研究的研究质量评价[J].中国循证医学杂志，2017，17（10）：1231-1236.
[16] 杨男，范红媛，田燕，等.我国中药药物经济学研究系统评价和质量评估[J].中国研究型医院，2017，4（6）：50-58.

相似文献/References:

[1]田梦媛,殷 潇,张欲晓,等.吉非替尼治疗晚期非小细胞肺癌的医保预算影响分析[J].卫生经济研究,2016,(12):25.
[2]黄泽华,潘 越,钭江苑,等.药物经济学在医保决策中的应用[J].卫生经济研究,2017,(03):37.
[3]肖 月,史黎炜,邱英鹏,等.内窥镜手术器械控制系统应用的预算影响分析[J].卫生经济研究,2018,(06):15.
[4]董心月,张伶俐,邵 蓉.英国价值定价理念与药品补偿制度的衔接及启示[J].卫生经济研究,2018,(10):54.
　DONG Xin-yue,ZHANG Ling-li,SHAO Rong.The Connection and Enlightenment of British Value Pricing Concept and Drug Compensation System[J].Journal Press of Health Economics Research,2018,(06):54.
[5]陈平钰,李洪超,马爱霞.直接抗病毒药物治疗慢性丙型肝炎患者的预算影响分析[J].卫生经济研究,2019,(01):44.
　CHEN Ping-yu,LI Hong-chao,MA Ai-xia.Budgetary Impact Analysis of Direct Antiviral Drugs in the treatment of Patients with Chronic Hepatitis C[J].Journal Press of Health Economics Research,2019,(06):44.
[6]柳鹏程,李 灿,杜 怿,等.中国医保预算影响分析的研究范式[J].卫生经济研究,2021,38(1):40.
　LIU Peng-cheng,LI Can,DU Yi,et al.Research Paradigm of Impact Analysis on Medical Insurance Budget in China[J].Journal Press of Health Economics Research,2021,38(06):40.
[7]杨越茗,唐文熙,刘永军.药物经济学评价中患者用药依从性的识别、测量与估值[J].卫生经济研究,2021,38(11):18.
　YANG Yue-ming,TANG Wen-xi,LIU Yong-jun.Identification, Measurement and Evaluation of Patients' Drug Compliance in Pharmacoeconomic Evaluation[J].Journal Press of Health Economics Research,2021,38(06):18.
[8]胡善联.中国医保药品价格谈判回顾和展望[J].卫生经济研究,2024,41(01):9.
　HU Shanlian.Review and Prospects of Medical Insurance Price Negotiation in China[J].Journal Press of Health Economics Research,2024,41(06):9.

更新日期/Last Update: 2020-06-04